Ethic Inc. Takes Position in argenx SE (NASDAQ:ARGX)

Ethic Inc. purchased a new position in shares of argenx SE (NASDAQ:ARGX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,230 shares of the company’s stock, valued at approximately $756,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stephens Inc. AR acquired a new stake in shares of argenx in the 4th quarter worth $310,000. Ritholtz Wealth Management lifted its stake in shares of argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after purchasing an additional 414 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of argenx by 40.0% in the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company’s stock worth $1,042,000 after buying an additional 484 shares in the last quarter. Finally, Atomi Financial Group Inc. acquired a new stake in argenx during the 4th quarter valued at $339,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARGX. Robert W. Baird upgraded argenx from a “neutral” rating to an “outperform” rating and set a $680.00 price objective for the company in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $720.00 target price on shares of argenx in a report on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Sanford C. Bernstein upgraded argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Two analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $698.11.

argenx Stock Performance

Shares of ARGX opened at $532.27 on Thursday. argenx SE has a 52-week low of $356.38 and a 52-week high of $678.21. The firm has a market cap of $32.50 billion, a PE ratio of -604.85 and a beta of 0.57. The business’s 50 day moving average price is $592.11 and its two-hundred day moving average price is $612.79.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.32 by $0.26. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.